Women were less than half of the people tested for almost all of these common medicines.

ADHD

methylphenidate

More and more women are diagnosed with ADHD as adults, but only about a third of the people in its studies were women, and most studies were in children.

  • 34.9%

    of the people in the studies were women

  • 54%

    of studies did not allow pregnant women

  • 1%

    looked at results for women separately

Was someone like me tested?

Choose the group that fits you.

Not one of these studies reported results separately for any of the groups below.

Not studied

Pregnant women

54% of studies would not let pregnant women join, and we found no study that tested this medicine in pregnancy.

What do we know?

What the FDA drug label says

Studies of pregnant women give mixed answers about birth defects and miscarriage. A national registry is collecting more data (1-866-961-2388).

What women report more

Compared with men taking the same medicine.

  • 2.3×Mouth and gum problems
  • 2.3×Allergic reactions
  • 2.2×Hives and swelling of the face, lips or throat
  • 1.9×Headaches

How many times more often women reported each problem than men taking the same medicine, based on reports to the FDA. This is a warning sign, not proof the medicine caused it.

Make it about you

Check it against your medicines

Check methylphenidate against the medicines, pregnancy and birth control in your profile.

Join to check

Women's experiences

Join or sign in to share, like or save. You'll fill in a short health profile so your story has context and we can check your medicines.

No one has shared yet. Your story could help the next woman.

All the details

Every number behind this page.

Who was in the studies

11,506 people in 110 studies

4,016 womenmiddle line = equal numbers7,490 men

Race

  • White76.4%
  • Black / African American12.7%
  • More than one race4.6%
  • Asian2.1%
  • Hispanic / Latina1.2%

Studies didn't say how many of the women were Black, Asian or another race — only totals for everyone.

Hispanic or Latina
29.1%
Age 65 or older
3.3%
Studies with men only
0
Studies with women only
0
Rules that kept women out

Share of studies with each rule.

  • 85%

    No mental health conditions

    Women with depression, bipolar disorder or other mental health conditions were turned away.

    See the exact rule
    “…ontrolled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post traumatic stress…” NCT01552902
  • 77%

    Age limit under 65

    Older women were turned away, even though they often take this medicine.

    See the exact rule
    “Maximum age: 17 Years.” NCT01552902
  • 61%

    No seizures

    Women with epilepsy or past seizures were turned away.

    See the exact rule
    “Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.” NCT01552902
  • 54%

    No pregnant women

    Women who were pregnant could not join.

    See the exact rule
    “Subject is female and is pregnant or lactating.” NCT01552902
  • 36%

    No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    See the exact rule
    “Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems tha…” NCT01552902
  • 28%

    Had to use birth control

    Women who couldn't or didn't want to use birth control were turned away.

    See the exact rule
    “Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable contraceptive requirements of the protocol.” NCT01552902
What nobody checked

Share of studies that recorded each thing.

  • 1%
    Results shown separately for women
  • 0%
    Whether anyone was pregnant
  • 0%
    Whether women were past menopause
  • 3%
    Body weight (BMI)
  • 21%
    Hispanic / Latina or not
  • 41%
    Race
All 110 studies

Study titles and rules are shown in their original English.

StudyPhasepeople% women
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
NCT01552902
454734%
Learning Impairments Among Survivors of Childhood Cancer
NCT00576472
446943.5%
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
NCT01552915
445933.6%
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
NCT00922636
2/334029.4%
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
NCT00763971
333219.3%
Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
NCT00264797
330321.1%
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
NCT01338818
329846.3%
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00758160
429616.6%
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
NCT00714688
327947.7%
Examining Tolerance to CNS Stimulants in ADHD
NCT02039908
426720.2%
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00253747
325543.5%
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
NCT00183391
423227.2%
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
NCT01239030
323033%
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
NCT01109849
323026.5%
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
NCT00889915
422831.6%
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
NCT00499863
321725.3%
Interventions for Children With Attention and Reading Disorders
NCT01133847
421638.9%
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
NCT00429273
420731.4%
Apathy in Dementia Methylphenidate Trial 2
NCT02346201
319934.2%
Methylphenidate and a Nursing Telephone Intervention for Fatigue
NCT00424099
2/319067.4%
Attention Deficit Disorder Medication Response Study
NCT01727414
417128.7%
Treatment of Severe Childhood Aggression (The TOSCA Study)
NCT00796302
416823.2%
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
NCT01933880
416822%
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
NCT00776009
416543%
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
NCT00501293
316325.2%
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
NCT02520388
316129.8%
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00307684
315545.8%
Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
NCT00181714
415426%
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
NCT00050622
—15415.6%
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
NCT00428792
315025.3%
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
NCT00602290
414354.5%
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
NCT03185065
314177.3%
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
NCT00376675
313960.4%
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
NCT01012622
413617.6%
Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
NCT02153944
412851.6%
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
NCT02493777
311731.6%
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01060150
411323.9%
The Effects of ADHD Medication (TEAM) Study
NCT02293655
410933.9%
Behavioral Differences in Effortful Control
NCT01852344
—10862.8%
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00409708
210436.5%